IASLC 2020: liquid biopsy for advanced non-small-cell lung cancer

Written by Louis Gautier, Future Science Group

liquid biopsy

Researchers from Princess Margaret Cancer Centre (Toronto, Canada) have tested the feasibility, clinical utility and treatment outcomes of using liquid biopsy for molecular diagnosis of NSCLC in the Canadian healthcare system. The results presented recently at the IASLC 2020 Lung Cancer Hot Topic: Liquid Biopsy Virtual Conference (2–3 October), show that actionable genomic targets are determined more frequently with liquid biopsy. They discuss the additional treatment options that result from such molecular testing and encourage further research into its implementation into healthcare. Since its advent in 2018, liquid biopsy and the ‘blood-first’ approach to molecular profiling and diagnosis has been...

To view this content, please register now for access

It's completely free